CoChat

A Novel Solid Lipid Nanoparticle Formulation for Active Targeting to Tumor αvβ3 Integrin Receptors Reveals Cyclic RGD as A Double‐Edged Sword

Shuhendler, Adam J., Prasad, Preethy, Leung, Michael, Rauth, Andrew M., DaCosta, Ralph S., Wu, Xiao Yu · 2012 · Advanced Healthcare Materials
Cited by 111

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

The overexpression of α v β 3 integrin receptors on tumor cells and tumor vascular endothelium makes it a useful target for imaging, chemotherapy and anti‐angiogenic therapy. However integrin‐targeted delivery of therapeutics by nanoparticles have provided only marginal, if any, enhancement of therapeutic effect. This work was thus focused on the development of novel α v β 3‐targeted near infrared light‐emitting solid lipid nanoparticles (SLN) through conjugation to the α v β 3 integrin‐specific ligand cyclic Arg‐Gly‐Asp (cRGD), and the assessment of the effects of α v β 3 targeting on nanoparticle biodistribution. Since our previously developed non‐targeted “stealth” SLN showed little hepatic accumulation, unlike most reported liposomes and micelles, they served as a reference for quantifying the effects of cRGD‐conjugation on tumor uptake and whole animal biodistribution of SLN. Non‐targeted SLN, actively targeted (RGD‐SLN) and blocked RGD‐SLN were prepared to contain near infrared quantum dots for live animal imaging. They were injected intravenously to nude mice bearing xenograft orthotopic human breast tumors or dorsal window chamber breast tumors. Tumor micropharmacokinetics of various SLN formulations were determined using intravital microscopy, and whole animal biodistribution was followed over time by optical imaging. The active tumor targeting with cRGD was found to be a “double‐edged sword”: while the specificity of RGD‐SLN accumulation in tumor blood vessels and their tumor residence time increased, their distribution in the liver, spleen, and kidneys was significantly greater than the non‐targeted SLN, leaving a smaller amount of nanoparticles in the tumor tissue. Nevertheless the enhanced specificity and retention of RGD‐SLN in tumor neovasculature could make this novel formulation useful for tumor neovascular‐specific therapies and imaging applications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/adhm.201200006

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 111

Metadata

Authors
Shuhendler, A. J., Prasad, P., Leung, M., Rauth, A. M., DaCosta, R. S., & Wu, X. Y.
Venue
Advanced Healthcare Materials
Publisher
Wiley
Published
2012-07-25
Volume
1
Issue
5
Pages
600-608
ISSN
  • 2192-2640 (ISSN-L)
  • 2192-2659
OpenAlex
W2000403276
Cited by
111
References
1
FWCI
3.13
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel Solid Lipid Nanoparticle Formulation for Active Targeting to Tumor αvβ3 Integrin Receptors Reveals Cyclic RGD as A Double‐Edged Sword. https://app.cochat.ai/papers/10.1002/adhm.201200006
The paper
Shuhendler, A. J., Prasad, P., Leung, M., Rauth, A. M., DaCosta, R. S., & Wu, X. Y. (2012). A Novel Solid Lipid Nanoparticle Formulation for Active Targeting to Tumor αvβ3 Integrin Receptors Reveals Cyclic RGD as A Double‐Edged Sword. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.201200006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.